| Sign In to gain access to subscriptions and/or personal tools. |
Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for PsychopharmacologyPsychopharmacology Unit, University of Bristol, Bristol, UK, david.j.nutt{at}bristol.ac.uk
University of Nottingham, Nottingham UK
MRC Social Genetic Developmental Psychiatry, Institute of Psychiatry, Kings College London, UK
Telford & Wrekin PCT, Shrewsbury, UK
London, UK
University of Dundee, Dundee UK
Psychopharmacology Unit, University of Bristol, Bristol, UK
Institute of Psychiatry, London, UK
University of Southampton, Southampton, UK
Institute of Psychiatry, London, UK
University of British Columbia, Vancouver, Canada
Bethlem Royal Hospital, Kent, UK Attention-deficit/hyperactivity disorder (ADHD) is an established diagnosis in children, associated with a large body of evidence on the benefits of treatment. Adolescents with ADHD are now leaving childrens services often with no readily identifiable adult service to support them, which presents problems as local pharmacy regulations often preclude the prescription of stimulant drugs by general practitioners (GPs). In addition, adults with ADHD symptoms are now starting to present to primary care and psychiatry services requesting assessment and treatment. For these reasons, the British Association for Psychopharmacology (BAP) thought it timely to hold a consensus conference to review the body of evidence on childhood ADHD and the growing literature on ADHD in older age groups. Much of this initial guidance on managing ADHD in adolescents in transition and in adults is based on expert opinion derived from childhood evidence. We hope that, by the time these guidelines are updated, much evidence will be available to address the many directions for future research that are detailed here.
Key Words: ADHD hyperkinetic disorders hyperactivity impulsivity psychostimulants psychotherapy co-morbidities
This version was published on January
1, 2007 Journal of Psychopharmacology, Vol. 21, No. 1,
10-41 (2007) This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



